CD274 and non-small cell lung carcinoma: In the Phase III clinical study SKYSCRAPER-01, the combination therapy of tiragolumab and Tecentriq was evaluated as a first-line treatment for patients with locally advanced or metastatic NSCLC exhibiting high PD-L1 expression.